Abstract
Objective: Glucocorticoids are well-known regulators of adipose tissue metabolism and endocrine
function. The aim of this study was to examine glucocorticoid effect on plasminogen
activator inhibitor 1 (PAI-1), tumour necrosis factor alpha (TNFα), leptin and interleukin-6
(IL-6) adipose tissue secretion. Material and Methods: Twelve healthy postmenopausal women with mean BMI of 28.9 kg/m² (± 0.8 SEM) received
25 mg prednisolone daily for 7 days. Before and after glucocorticoid treatment adipose
tissue secretion of PAI-1, leptin, IL-6 and TNFα were measured, and adipocyte PAI-1
mRNA as well as anthropometrical and bio-chemical data were obtained. Results: Anthropometric measurements remained unaffected. Analyses of venous blood-samples
showed a borderline increase of insulin levels (p = 0.062). PAI-1 secretion from adipose
tissue increased (1.9 ± 0.2 vs. 3.5 ± 0.5 ng/g triglycerides, p = 0.012), but PAI-1
mRNA levels did not (0.19 ± 0.02 vs. 0.21 ± 0.04 arbitrary units after normalised
to β-actin, p = 0.51). There were no apparent differences in IL-6, TNFα or leptin
secretion after glucocorticoid exposure. Conclusion: This study shows an increased secretion of PAI-1, but not IL-6, TNFα or leptin, from
abdominal adipose tissue after in vivo glucocorticoid treatment, which may be a finding of pathophysiological importance
given the well-known effect of glucocorticoid excess on metabolic aberrations and
cardiovascular morbidity.
Key words
Adipose Tissue - Glucocorticoids - Obesity - PAI-1 and Protein Secretion
References
- 1
Kirk L F, Hasch R B, Katner H P, Jones T.
Cushing’s disease: clinical manifestations and diagnostic evaluation.
Amer Fam Physician.
2000;
62
1119-1127
- 2
Rosmond R, Bjorntorp P.
The interactions between hypothalamic-pituitary- adrenal axis activity, testosterone,
insulin-like growth factor I and abdominal obesity with metabolism and blood pressure
in men.
Int J Obes Relat Metab Disord.
1998;
22
1184-1196
- 3
Bjorntorp P, Rosmond R.
Obesity and cortisol.
Nutrition.
2000;
16
924-926
- 4
Ottosson M, Lonnroth P, Bjorntorp P, Eden S.
Effects of cortisol and growth hormone on lipolysis in human adipose tissue.
J Clin Endocrinol Metab.
2000;
85
799-825
- 5
Arner P.
Regional differences in protein production by human adipose tissue.
Biochem Soc Trans.
2001;
29
72-75
- 6
Alessi M C, Morange P, Juhan-Vague I.
Fat cell function and fibrinolysis.
Horm Metab Res.
2000;
32
504-508
- 7
Juhan-Vague I, Alessi M C, Morange P E.
Hypofibrinolysis and increased PAI-1 are linked to atherosclerosis via insulin resistance
and obesity.
Ann Med.
2000;
32
78-84
- 8
Janand-Delenne B, Chagnaud C, Raccah D, Alessi M C, Juhan-Vague I, Vague P.
Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women.
Int J Obes.
1998;
22
312-317
- 9
Patrassi G M, Sartori M T, Livi U, Casonato A, Danesin C, Vettore S, Girolami A.
Impairment of fibrinolytic potential in long-term steroid treatment after heart transplantation.
Transplantation.
1997;
64
1610-1614
- 10
Mohamed-Ali V, Pinkney J H, Coppack S W.
Adipose tissue as an endocrine and paracrine organ.
Int J Obes Relat Metab Disord.
1998;
22
1145-1158
- 11
Grimble R F.
Inflammatory status and insulin resistance.
Curr Opin Clin Nutr Metab Care.
2002;
5
551-559
- 12
He G, Pedersen S B, Bruun J M, Richelsen B.
Regulation of plasminogen activator inhibitor-1 in human adipose tissue; interaction
between cytokines, cortisol and estrogen.
Horm Metab Res.
2000;
32
515-520
- 13
Lasic S, Bobarevic N, Nikolin B.
Simultaneous determination of prednisone, prednisolone, cortisol and dexamethasone
in plasma by high-performance liquid chromatography.
J Pharm Biomed Anal.
1989;
7
777-782
- 14
Kvist H, Chowdhury B, Grangård U, Tylén U, Sjöström L.
Total and visceral adipose-tissue volumes derived from measurements with computed
tomography in adult men and women: predictive equations.
Am J Clin Nutr.
1988;
48
1351-1361
- 15
Morange P E, Aubert J, Peiretti F, Lijnen H R, Vague P, Verdier M, Negrel R, Juhan-Vague I,
Alessi M C.
Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by
human adipose tissue.
Diabetes.
1999;
48
890-895
- 16
Seki T, Miyasu T, Noguchi T, Hamasaki A, Sasaki R, Ozawa Y, Okukita K, Declerck P J,
Ariga T.
Reciprocal regulation of tissue-type and urokinase-type plasminogen activators in
the differentiation of murine preadipocyte line 3T3-L1 and the hormonal regulation
of fibrinolytic factors in the mature adipocytes.
Cell Physiol.
2001;
189
72-78
- 17
Halleux C M, Declerck P J, Tran S L, Detry R, Brichard S M.
Hormonal control of plasminogen activator inhibitor-1 gene expression and production
in human adipose tissue: Stimulation by glucocorticoids and inhibition by catecholamines.
J Clin Endocrinol Metab.
1999;
84
4097-4105
- 18
Sartori M T, Patrassi G M, Pontarollo S, Livi U, Angelini A, Theodoridis P, Fioretti M,
Girolami A.
relation between long-term steroid treatment after heart transplantation, hypofibrinolysis
and myocardial microthrombi generation.
J Heart Lung Transplant.
1999;
18
693-700
- 19
Mohamed-Ali V, Pinkney J H, Panahloo A, Cwyfan-Hughes S, Holly J MP, Yudkin J S.
Insulin-like growth factor binding protein-1 in NIDDM: relationship with the insulin
resistance syndrome.
Clin Endocrinol.
1999;
50
221-228
- 20
Eriksson P, Reynisdottir S, Lonnqvist F, Stemme V, Hamsten A, Arner P.
Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese
individuals.
Diabetologia.
1998;
41
65-71
- 21
Alessi M C, Morange P, Juhan-Vague I.
Fat cell function and fibrinolysis.
Horm Metab Res.
2000;
32
504-508
- 22
Patrassi G M, Sartori M T, Viero M L, Scarano L, Boscaro M, Girolami A.
The fibrinolytic potential in patients with Cushing’s disease: a clue to their hypercoagulable
state.
Blood Coag Fibrinol.
1992;
3
789-793
- 23
Yamamoto K R.
Steroid receptor regulated transcription of specific genes and gene networks.
A Rev Genet.
1985;
19
209-252
- 24
van Zonneveld A J, Curriden S A, Loskutoff D J.
Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid
regulation of its promoter.
Proc Natl Acad Sci USA.
1988;
85
5525-5529
- 25
Brown N J, Kim K S, Chen Y Q, Blevins L S, Nadeau J H, Meranze S G, Vaughan D E.
Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator
inhibitor-1.
production.
2000;
85
336-344
- 26
Song C Z, Tian X, Gelehrter T D.
Glucocorticoid receptor inhibits transforming growth factor-beta signalling by directly
targeting the transcriptional activation function of Smad 3.
Proc Natl Acad Sci USA.
1999;
96
11 776-11 781
- 27
Vincennati V, Vottero A, Friedman C, Papanicolaou D A.
Hormonal regulation of interleukin-6 production in human adipocytes.
Int J Obes Relat Metab Disord.
2002;
26
905-911
- 28
Mazusaki H, Ogawa Y, Hosoda K, Miyawaki T, Hanaoka I, Hiraoka J, Yasuno A, Nishimura H,
Yoshimasa Y, Nishi S, Nakao K.
Glucocorticoid regulation of leptin synthesis and secretion in humans: Elevated plasma
leptin levels in Cushing’s syndrome.
J Clin Endocrinol Metab.
1997;
82
2542-2547
- 29
Fried S K, Bunkin D A, Greenberg A S.
Omental and subcutaneous adipose tissues of obese subjects release interleukin-6:
depot difference and regulation by glucocorticoid.
J Clin Endocrinol.
Metab1998;
83
847-850
- 30
Halleux C M, Servais I, Reul B A, Detry R, Brichard S M.
Multihormonal control of ob gene expression and leptin secretion from cultured human
visceral adipose tissue: increased responsiveness to glucocorticoids in obesity.
J Clin Endocrinol Metab.
1998;
83
902-909
- 31
Papaspyrou-Rao S, Schneider S H, Petersen R N, Fried S K.
Dexamethasone increases leptin expression in humans in vivo.
J Clin Endocrinol Metab.
1997;
82
1635-1637
- 32
Berg A L, Nilsson-Ehle P.
Direct effects of corticotropin on plasma lipoprotein metabolism in man - studies
in vivo and in vitro.
Metabolism.
1994;
43
90-97
- 33
Berg A L, Nilsson-Ehle P, Arnadottir M.
Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function
in patients with membranous nephropathy.
Kidney Int.
1999;
56
1534-1543
- 34
McMahon M, Gerich J, Rizza R.
Effects of glucocorticoids on carbohydrate metabolism.
Diabetes Metab Rev.
1988;
4
17-30
J. Hoffstedt, M.D., Ph.D.
Karolinska Institutet
M61, CME · Huddinge University Hospital · 141 86 Stockholm · Sweden ·
Phone: + 46 (8) 58 58 00 00
Email: johan.hoffstedt@medhs.ki.se